Bisphosphonates and Osteonecrosis of the Jaw
Authors: Andrew Grey, Tim Cundy
Journal: Annals of Internal Medicine (2006)

Letters21 November 2006Bisphosphonates and Osteonecrosis of the JawAndrew Grey, MD and Tim Cundy, MDAndrew Grey, MDFrom the University of Auckland, Auckland, New Zealand.Search for more papers by this author and Tim Cundy, MDFrom the University of Auckland, Auckland, New Zealand.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-145-10-200611210-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Woo and colleagues (1) highlight the substantial difference in the risk for osteonecrosis of the jaw between patients with cancer who receive high doses of intravenous bisphosphonates and patients with nonmalignant skeletal disorders who receive considerably lower doses, but their recommendations for managing the disorder do not reflect the difference. Thus, they suggest that all patients starting bisphosphonate therapy undergo a comprehensive dental examination and panoramic and intraoral radiography followed by surgical treatment for “at-risk” teeth. The strategy is based on the recommended evaluation of patients who are about to undergo bone marrow transplantation—hardly a similar situation ...References1. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61. [PMID: 16702591] LinkGoogle Scholar2. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658-68. [PMID: 16383047] CrossrefMedlineGoogle Scholar3. American Dental Association. Osteonecrosis of the jaw. Chicago: American Dental Association. Accessed at www.ada.org/prof/resources/topics/osteonecrosis.asp on 20 May 2006. Google Scholar4. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005;182:413-5. [PMID: 15850439] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Andrew Grey, MD; Tim Cundy, MDAffiliations: From the University of Auckland, Auckland, New Zealand.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws Sook-Bin Woo , John W. Hellstein , and John R. Kalmar Bisphosphonates and Osteonecrosis of the Jaw Nelson B. Watts , Steven T. Harris , Michael R. McClung , John P. Bilezikian , Susan L. Greenspan , and Marjorie M. Luckey Bisphosphonates and Osteonecrosis of the Jaw Sook-Bin Woo , John W. Hellstein , and John R. Kalmar Metrics Cited byTreatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifeneInsight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical managementRationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal womenOsteonecrosis of the jaw and bisphosphonate treatment for osteoporosisCurrent awareness: Pharmacoepidemiology and drug safety 21 November 2006Volume 145, Issue 10Page: 791KeywordsBone marrowConflicts of interestDiagnostic radiologyHealth careOsteoporosisSurgery ePublished: 21 November 2006 Issue Published: 21 November 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...